Bioequivalence of Cladribine 10 mg from two different products

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508656-19-00

Acronym

CPO23001

Enrollment

Registered

2024-02-06

Start date

2024-03-01

Completion date

2024-05-02

Last updated

2024-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

Interventions

None listed

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Countries

Bulgaria

Outcome results